Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model.
about
Integrative meta-analysis identifies microRNA-regulated networks in infantile hemangiomaPrognostic value of IGF-1R expression in bone and soft tissue sarcomas: a meta-analysis.Spotlight on olaratumab in the treatment of soft-tissue sarcoma: design, development, and place in therapy.Kinase inhibitors of the IGF-1R as a potential therapeutic agent for rheumatoid arthritis.
P2860
Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Doxorubicin plus the IGF-1R an ...... tudy using the TITE-CRM model.
@ast
Doxorubicin plus the IGF-1R an ...... tudy using the TITE-CRM model.
@en
type
label
Doxorubicin plus the IGF-1R an ...... tudy using the TITE-CRM model.
@ast
Doxorubicin plus the IGF-1R an ...... tudy using the TITE-CRM model.
@en
prefLabel
Doxorubicin plus the IGF-1R an ...... tudy using the TITE-CRM model.
@ast
Doxorubicin plus the IGF-1R an ...... tudy using the TITE-CRM model.
@en
P2093
P2860
P356
P1433
P1476
Doxorubicin plus the IGF-1R an ...... tudy using the TITE-CRM model.
@en
P2093
B Brockstein
D G Thomas
J D Zavala
K A Griffith
S D Undevia
S M Schuetze
W M Stadler
P2860
P304
P356
10.1093/ANNONC/MDV171
P577
2015-04-09T00:00:00Z